Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Discovery themes featuring this stock| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
378.00 | 2,662 Cr | 10.53 | 0.98 | 0.00 | 2.88 | 3.79 | 6.77 | ||
560.00 | 2,478 Cr | 173.65 | 5.05 | 0.00 | 2.91 | 2.79 | — | ||
2338.95 | 2,424 Cr | 35.99 | 7.33 | 0.00 | 20.31 | 21.46 | 11.37 | ||
181.35 | 2,237 Cr | -45.83 | 1.87 | 0.33 | 3.03 | 3.56 | -2.06 | ||
1602.25 | 2,142 Cr | 20.83 | 3.23 | 0.00 | 15.49 | 19.85 | 12.04 | ||
205.40 | 1,897 Cr | -19.94 | 2.02 | 0.10 | -10.13 | 0.77 | -3.81 | ||
813.60 | 1,810 Cr | 59.39 | 5.58 | 0.00 | 9.40 | 12.54 | 6.34 | ||
| Median: 7 Co. | — | 560.00 | 2,237 Cr | 20.83 | 3.23 | 0.00 | 3.03 | 3.79 | 6.55 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Hikal Limited is an Indian fine chemicals and CDMO company supplying APIs, advanced intermediates, crop protection actives, animal health APIs and specialty chemicals globally, operating five manufacturing sites and an R&T centre with a focus on contract development and manufacturing services for global innovators and customers across Americas, Europe, Japan, LATAM and RoW.
Q3 FY26 marked a clear operational recovery for Hikal Limited after regulatory remediation: consolidated revenue recovered to INR494 crore and EBITDA expanded to INR83 crore, driven by resumed pharmaceutical supplies, improved capacity utilization and remediation largely completed at the inspected facility, restoring near‑term commercial momentum.
Strategic investments made over the past 12–18 months — including a High‑Potency API (HPAPI) laboratory, a new pilot plant and two multipurpose facilities — are now operational, materially enhancing Hikal Limited’s differentiated CDMO positioning for oncology and other high‑barrier small molecules and improving medium‑term revenue visibility.
The Crop Protection division faces structural pricing pressure from China and global overcapacity, prompting Hikal Limited to accelerate portfolio diversification into Personal Care and Specialty Chemicals (HiZenn, HiFend) with commercialisation expected to meaningfully contribute to revenues in FY27 and beyond.
Balance sheet and cash flows show improving discipline: 9M FY26 operating cash generation remained robust despite a temporary P&L impact from a one‑time labour code exceptional item, with targeted, contract‑led capex and a management commitment to reduce net debt as operating leverage returns.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,226 Cr
High Risk
-45.6
34.1
2.0
1.9
386.00
145.95
Sales CAGR
Profit CAGR
ROE
ROCE
Hikal Ltd (HIKAL) is currently trading at 180.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Hikal Limited is an Indian fine chemicals and CDMO company supplying APIs, advanced intermediates, crop protection actives, animal health APIs and specialty chemicals globally, operating five manufacturing sites and an R&T centre with a focus on contract development and manufacturing services for global innovators and customers across Americas, Europe, Japan, LATAM and RoW. Q3 FY26 marked a clear operational recovery for Hikal Limited after regulatory remediation: consolidated revenue recovered to INR494 crore and EBITDA expanded to INR83 crore, driven by resumed pharmaceutical supplies, improved capacity utilization and remediation largely completed at the inspected facility, restoring near‑term commercial momentum. Strategic investments made over the past 12–18 months — including a High‑Potency API (HPAPI) laboratory, a new pilot plant and two multipurpose facilities — are now operational, materially enhancing Hikal Limited’s differentiated CDMO positioning for oncology and other high‑barrier small molecules and improving medium‑term revenue visibility. The Crop Protection division faces structural pricing pressure from China and global overcapacity, prompting Hikal Limited to accelerate portfolio diversification into Personal Care and Specialty Chemicals (HiZenn, HiFend) with commercialisation expected to meaningfully contribute to revenues in FY27 and beyond. Balance sheet and cash flows show improving discipline: 9M FY26 operating cash generation remained robust despite a temporary P&L impact from a one‑time labour code exceptional item, with targeted, contract‑led capex and a management commitment to reduce net debt as operating leverage returns.
Over the past 52 weeks, Hikal Ltd has traded between a low of ₹145.95 and a high of ₹386.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Hikal Ltd has a market capitalization of approximately 2,236.68. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Hikal Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -45.83 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,236.68 Cr, Hikal Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Hikal Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Hikal Ltd is -45.83. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Hikal reported Q4 FY25 revenue of ₹552 crore and EBITDA of ₹123 crore, with EBITDA margin improving to about 22.4% (also cited as 22.3%).
Bearish
5
Neutral
2
Bullish
7
Bearish
35
Neutral
2
Bullish
9
Bearish
30
Neutral
0
Bullish
2
